RCRS Email Update July 4, 2003 (updated February 12, 2004)

It is quite an amazing thing that from out of the University of Edinburgh, the home of the
researcher John Beard, come new findings about the cell of eternal youth or "germ cells",
as Beard termed them, the progenitor cells of all mammalian life, and at the same time, the
very cells that, alone, can evolve both body cells (soma) and placental cells (trophoblasts).

It was Beard's assertion that cancers of all kinds were trophoblasts operating outside the
normal canalization of pregnancy, a "natural phenomena", and not a disease.

It was for me a matter of inductive reasoning that called to mind the fact that if only a
totipotent cell can express both somatic tissues AND placental tissues, that if cancer arises
in man outside of pregnancy, then it follows that man must possess cells with complete potency
or STEM Cells.  Cells able to differentiate in all directions.  In other words, cancer is proof of
stem cells obviating any need for seeking out fetal cells or cloning embryonic stem cells.

The early 20th century conclusion by Beard that all cancer was related to pregnancy
trophboblasts...outside of pregnancy... was proven in the 1990s by Dr. Hernan Acevedo et al.,
on genetic grounds, that all cancers, regardless of type or origin (pathological samples as well
as petri dish cultures), express trophoblastic properties, most significantly the pregnancy
hormone human chorionic gonadotropin (hCG-beta).  This work, using the most sensitive
techniques innovated in part by Dr. Acevedo (flow cytometry) validated Beard's contention that
cancer is trophoblast.

We have of course known that cells with pleuripotency exist in the body, able to change roles
between closely related but still diverse cell systems, but that a diploid totipotent cell exists
able to express any and all body tissues AND the trophoblasts...normally seen only in
pregnancy...has been up to now only a deductive or circumstantial conclusion.  Now we have
evidence that is founded on genetics, the bedrock of cellular biology.  This gene cluster has been
termed after the Celtic mythical lore concerning the "land of eternal youth", or Tir nan Og, or nanog
gene cluster.

Frustratingly, going directly to the University web site will deliver little information on this
finding, which I read about in the Oregonian, as a reprint of Rick Weiss' article for the
LA Times-Washingon Post Service.  The article quotes Dr. Austin Smith, the U. of Edinburgh
researcher who led one of the two teams who announced their results in the journal Cell on
Friday, May 30, 2003.

Internet references follow this update, below.

The interesting point here is that the commonly accepted facts surrounding pregnancy
trophoblasts have as yet to be applied generally to cancers of all types, despite Dr. Acevedo's
findings.  In this regard, one naturally wonders what secrets pertinent to birth might apply to
cancer regression.  For example, amongst non-enzymatic therapies proven to affect
trophoblasts is the abortifacient RU-486.  And yet not one oncologist is familiar enough with the
rationales concerning the trophoblastic facts of cancer to make a connection between this drug
and cancer therapy.  Not that we consider this the ideal method. Any abortifacient affecting
trophoblast will affect cancer. Period. But many of these are toxic to normal cells as well.
There is a better way.

To recapitulate: We now know that trophoblasts arise within the non-pregnant human, and it is
always known as cancer.  We also know that amongst the factors inducing birth in
pregnancy . . . the systemic pancreatic enzymes . . . also apply towards cancer regression,
as proven by the fact of cancer cures with these very enzymes.  The National Institutes of Health
have funded Dr. Nicholas Gonzalez to elucidate the use of these enzymes in cancer therapy, for
which readers are encouraged to search on the internet.

No one applying enzymatic research in clinical venues that I know of apply them according to
the ideals elucidated by John Beard and further elucidated biochemical considerations of
trophoblasts, which we have done.  An associate of ours has been applying the protocols, as
we deem them most ideally, with impressive results.  We have seen successes in regressing
lymphomas, breast cancers, glioma, and several other types of cancer.  The basic Beardian
tenant on this is that amongst the enzymes used, we want to see amylase applied at least
double in amount over the proteases.  The rationales for the immuno-enzyme therapy we
support can be read at (a work in progress):

www.navi.net/~rsc/iet_txt.html

This is a free service to RCRS email update subscribers. The same information and a host of
other confirmatory data is also for sale as a CD Rom for 25 dollars from RCRS.  Contact for
further information.

For reference, go to:

http://www.sciencedaily.com/releases/2003/06/030602024530.htm

http://www.cell.com/

http://www.icscottishrecruitment.co.uk/career/detail.cfm?newsid=188

http://www.fass.org/fasstrack/news_item.asp?news_id=1299

http://www.research-innovation.ed.ac.uk/commercial/collaboration/intracellularis.htm

http://www.research-innovation.ed.ac.uk/commercial/expertise/lifesciences/cgr.htm

http://search.boston.com/dailyglobe2/150/nation/Stem_cell_researchers_find_master_gene_+.shtml

http://www.ed.ac.uk/news/